drugset
drugset / Trial / NCT06986434

CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic Differentiation

NCT06986434 ↗

Phase 0 Not yet recruiting 20 enrolled Affiliated Hospital to Academy of Military Medical Sciences
NaSingle-groupOpen-labelTreatment

Summary

This is a single arm study to evaluate the safety and efficacy of CAR19BCMA CAR-T cells in the treatment of relapsed/refractory CD19/BCMA positive plasma cell neoplasms and lymphomas/leukemias with plasmacytic differentiation.

Timeline

Start
2026-04-02
Primary completion
2027-05-22
Completion
2028-08-25

Drugs

EvaluationDrugModalityDoseRoute
Subject CAR19BCMA-T cells Unknown 1e+06 cells/kg Intravenous
Subject CAR19BCMA-T cells Unknown 2e+06 cells/kg Intravenous
Subject CAR19BCMA-T cells Unknown 3e+06 cells/kg Intravenous
Background Cyclophosphamide Other / unclassified 300 mg/m2 Intravenous
Background Fludarabine Small molecule 30 mg/m2 Intravenous

Indications

plasma cell neoplasm